Researchers in China's Shanghai city have announced preliminary success in developing a vaccine as the country is witnessing a rise in cases of humans getting affected by bird flu, or H7N9 virus.
Officials with Shanghai Public Health Clinical Center said that their genetically-engineered vaccine has passed the preliminary animal tests on mice, Xinhua reported.
The vaccine, however, will have to go through a clinical test to prove its effectiveness in protecting humans before being put into use, Xu Jianqing, a professor with the center, said.
Meanwhile, health authorities in Zhejiang province confirmed another human case of H7N9 bird flu, pushing the number of human cases in the province to 74 this year. The 61-year-old man is in a critical condition.
East China's Jiangsu province Saturday reported a human infection in a 53-year-old man, and one person's death due to bird flu, pushing the number of H7N9 human cases in the province to 12 this year.
An H7N9 virus was first reported to have infected humans in March 2013, in China.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
